Head-Neck Cetuximab

This collection combines advanced molecular imaging treatment response assessment through pre- and post-treatment FDG PET/CT scans with therapy of advanced head and neck cancer, including chemo-radiation therapy with and without addition of an EGFR inhibitor molecular targeted agent (Cetuximab).

The Head-Neck Cetuximab collection consists of a subset of image data from RTOG 0522/ACRIN 4500, which was randomized phase III Trial of Radiation Therapy and Chemotherapy for stage III and IV Head and Neck carcinomas. The RTOG 0522/ACRIN 4500 protocols were activated in November 2005 and successfully completed accrual of 945 patients in 2009. As part of the RTOG 0522 trial, institutions had the option to join the RTOG 0522/ACRIN 4500 imaging study. The post-treatment FDG PET/CT scan was performed 8-9 weeks after completion of treatment before any nodal dissection. For this reason the data was provided through two independent channels:

RTOG 0522: CT, Structures, RT Doses, RT Plans sent to ITC ACRIN 4500: Quantitative PET (PET/CT) sent to ACRIN For more information about the original aims of this trial please see this oral abstract: J Clin Oncol 29: 2011 (suppl; abstr 5500) here: https://meetinglibrary.asco.org/record/63118/video



最後更新 八月 16, 2019, 18:46 (CST)
建立 十月 15, 2018, 20:52 (CST)